{"version":"1.0","type":"link","title":"Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.","author_name":"Long GV 외","author_url":"https://prs-insight.online/author/Long%20GV","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/170829","thumbnail_width":1200,"thumbnail_height":630}